XIDORGEX
Live / Applied — Fourth extension granted (statement of use) (as of 01 Dec 2025)
What this means for you
Not registered yet, but its 17 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97799506
- Mark type
- Stylized text
- Filed
- 17 Feb 2023
- Published for opposition
- 05 Dec 2023
- Attorney of record
- Andrea Christensen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 02 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Dec 2025 — SOU EXTENSION 4 GRANTED
- 01 Dec 2025 — SOU EXTENSION 4 FILED
- 01 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 May 2025 — SOU EXTENSION 3 GRANTED
- 30 May 2025 — SOU EXTENSION 3 FILED
- 30 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2024 — SOU EXTENSION 2 GRANTED
- 21 Nov 2024 — SOU EXTENSION 2 FILED
- 21 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 May 2024 — SOU EXTENSION 1 GRANTED